Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Expression, Prognosis, and Immune Infiltrates Analyses of E2F-Related Transcription Factor Family in Human Brain and CNS Cancer
33 Pages Posted: 25 Jun 2020
More...Abstract
Background: We investigated the expression patterns, potential functions, unique prognostic value, and potential therapeutic targets of E2Fs in brain and CNS cancer and tumor-infiltrating immune cell microenvironments.
Methods: We analyzed E2Fs mRNA expression levels in diverse cancer types via Oncomine and GEPIA databases and diverse cancer cell lines via CCLE and EMBL-EBI databases, respectively. Furthermore, we evaluated the prognostic values using GEPIA database and the correlation of E2Fs expression with the abundance of immune infiltrates and the correlation between immune cell infiltration and GBM and LGG prognosis via TIMER database.
Findings: E2F1–8 expressions increased in most cancers compared with normal tissues, especially in brain and CNS cancer. E2F1–8 were highly expressed in most cancer cell lines, particularly neuroblastomas and gliomas. The higher expression of E2F1, -2, -4, -6, -7, and 8 indicated poor overall survival, and that of E2F2, -4, -7, and -8 indicated poor disease-free survival (both, p < 0·05) of all patients with LGG, but no significant correlation was found in GBM patients. Increased E2F3–6 and E2F1–8 expressions correlated with poor prognosis and increased immune infiltration levels in CD8+ T-cells, macrophages, neutrophils, and DCs in GBM and B-cells, CD8+ T-cells, CD4+ T-cells, macrophages, neutrophils, and DCs in LGG, respectively.
Interpretation: The E2F family showed significant expression differences between brain and CNS cancer and normal tissues. E2F1–8 and E2F2–8 could be hopeful prognostic biomarkers for GBM, and LGG, respectively. E2F3–6 and E2F1–8 could be likely therapeutic targets in patients with immune cell infiltration of GBM and LGG, respectively.
Funding Statement: No source of funding.
Declaration of Interests: No conflict of interest.
Keywords: Therapeutic target; Prognosis biomarker; Immune infiltrates; E2Fs; Brain and CNS cancer
Suggested Citation: Suggested Citation